Hymenoptera Venom Immunotherapy in DOGS: Safety and Clinical Efficacy
Preprint
- 28 August 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 g of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phase. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.Keywords
All Related Versions
- Version 1, 2023-08-28, Preprints
- Published version: Animals, 13 (19), 3002.
This publication has 40 references indexed in Scilit:
- Anaphylaxis to Stinging Insect VenomImmunology and Allergy Clinics of North America, 2022
- Hymenoptera venom immunotherapy without human serum albumin as a stabilizer in a canine patientVeterinary Record Case Reports, 2021
- Management of anaphylactic shock in the operating roomLa Presse Médicale, 2016
- Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rareJournal of Allergy and Clinical Immunology, 2014
- Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venomJournal of Allergy and Clinical Immunology, 2013
- Efficacy of venom immunotherapy given every 3 or 4 months: a prospective comparison with the conventional regimenAnnals of Allergy, Asthma & Immunology, 2013
- Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2Journal of Allergy and Clinical Immunology, 2012
- Venom immunotherapy for preventing allergic reactions to insect stings2010
- Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: The importance of baseline serum tryptase†Journal of Allergy and Clinical Immunology, 2010
- Clinical and immunologic follow-up of patients who stop venom immunotherapyJournal of Allergy and Clinical Immunology, 1991